NDAVAGINALINSERT, EXTENDED RELEASE
Approved
Mar 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
CERVIDIL (dinoprostone) by Ferring Pharmaceuticals is hormone. First approved in 1995.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERVIDIL (dinoprostone) is a prostaglandin analog administered as a vaginal insert for cervical ripening in pregnant women at or near term. It works by stimulating prostaglandin F2α production, which sensitizes the myometrium to oxytocin and initiates the cascade of events leading to labor. The drug promotes cervical changes including consistency modification, dilation, and effacement without initially affecting uterine contractions.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive positioning and likely smaller, experienced brand teams focused on market retention.
Mechanism of Action
hormone. In pregnancy, dinoprostone is secreted continuously by the fetal membranes and placenta and plays an important role in the final events leading to the initiation of labor including cervical ripening. Dinoprostone stimulates the production of prostaglandin F 2α ( PGF 2α), which sensitizes…
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening
Started Aug 2019
8 enrolled
Induction of Labor Affected Fetus / Newborn
An RCT of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt
Started Dec 2017
674 enrolled
Induction of Labor Affected Fetus / Newborn
Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert
Started Nov 2013
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
Started Sep 2010
1,358 enrolled
Reducing Time to Vaginal DeliveryCervical RipeningInduction of Labor
Open Label Comparative Trial of Dinoprostone Plus or Minus Oxytocin Versus Oxytocin Alone in Cervical Ripening for Labor Induction
Started Jun 2010
170 enrolled
Vaginal DeliveryCesarean Section
Worked on CERVIDIL at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.